|
Novel use of ctDNA to identify muscle-invasive and non-organ-confined upper tract urothelial carcinoma. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Merck |
Patents, Royalties, Other Intellectual Property - EGFR splice variant as a biomarker in renal cancer (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Leadership - Global Society of Rare Genitourinary Tumors; NCCN |
|
Other Relationship - NCCN |
(OPTIONAL) Uncompensated Relationships - Moffitt Cancer Center |
|
|
|
|
Stock and Other Ownership Interests - Predicine |
Patents, Royalties, Other Intellectual Property - Predicine |
|
|
No Relationships to Disclose |
|
|
|
Leadership - Singular Cure |
Stock and Other Ownership Interests - Predicine |
|
|
|
|
Stock and Other Ownership Interests - Predicine |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - crispr therapeutics; Guardant Health |
Consulting or Advisory Role - Arquer Diagnostics; Bristol-Myers Squibb; FerGene; Ferring |
Research Funding - CG Oncology |
Expert Testimony - CG Oncology |
Other Relationship - Predicine |